STOCK TITAN

Geovax Labs Inc Financials

GOVX
FY2025 annual
Revenue $2.5M -37.1% YoY
Net Income -$21.5M +14.1% YoY
EPS (Diluted) Not reported for FY2025
Free Cash Flow -$21.5M +12.9% YoY
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Geovax Labs Inc (GOVX) reported $2.5M in revenue for fiscal year 2025, down 37.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GOVX FY2025

GeoVax’s business model is still financing-led year after year, with research spending rather than sales determining how fast cash leaves the company.

In FY2025, operating cash burn nearly matched the reported loss at about -$21.5M, and capex was just $28K. Because cash use came from the research program rather than asset buildout, financing inflows of $19.1M functioned as operating fuel, not just balance-sheet reinforcement.

Across FY2024-FY2025, R&D remained the center of the cost structure at $23.7M and $18.1M, while revenue stayed comparatively small in both years. SG&A did not fall with R&D, remaining around $6.0M, so the lower loss reflects a narrower research push more than a wholesale slimming of the company’s fixed overhead.

The balance sheet is light on liabilities but not self-funding: cash ended FY2025 at $3.1M against current liabilities of $1.9M. Even after liabilities were pared back, the asset base kept shrinking from $8.2M to $6.3M, so each financing round is replenishing a smaller pool rather than supporting a cash-surplus model.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 31 / 100
Financial Health Score 31/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Geovax Labs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
26

Geovax Labs Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 26/100.

Growth
2

Geovax Labs Inc's revenue declined 37.1% year-over-year, from $4.0M to $2.5M. This contraction results in a growth score of 2/100.

Leverage
54

Geovax Labs Inc has a moderate D/E ratio of 0.66. This balance of debt and equity financing earns a leverage score of 54/100.

Liquidity
73

With a current ratio of 2.74, Geovax Labs Inc holds $2.74 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 73/100.

Cash Flow
2

Geovax Labs Inc's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.

Returns
31

Geovax Labs Inc posts a -561.2% return on equity (ROE), meaning it loses $561 for every $100 of shareholders' equity. This results in a returns score of 31/100. This is down from -495.0% the prior year.

Altman Z-Score Distress
-42.63

Geovax Labs Inc scores -42.63, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.7M) relative to total liabilities ($2.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/7

Geovax Labs Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing
N/A

Geovax Labs Inc reported a net loss of $21.5M while operations used $21.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$2.5M
YoY-37.1%
5Y CAGR+6.4%

Geovax Labs Inc generated $2.5M in revenue in fiscal year 2025. This represents a decrease of 37.1% from the prior year.

EBITDA
-$21.6M
YoY+13.9%

Geovax Labs Inc's EBITDA was -$21.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.9% from the prior year.

Net Income
-$21.5M
YoY+14.1%

Geovax Labs Inc reported -$21.5M in net income in fiscal year 2025. This represents an increase of 14.1% from the prior year.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$21.5M
YoY+12.9%

Geovax Labs Inc recorded an outflow of $21.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 12.9% from the prior year.

Cash & Debt
$3.1M
YoY-44.0%
5Y CAGR-20.8%
10Y CAGR+11.3%

Geovax Labs Inc held $3.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding
3M

Geovax Labs Inc had 3M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity
-561.2%
YoY-66.1pp
5Y CAGR-530.2pp

Geovax Labs Inc's ROE was -561.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 66.1 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$18.1M
YoY-23.6%
5Y CAGR+49.3%
10Y CAGR+26.8%

Geovax Labs Inc invested $18.1M in research and development in fiscal year 2025. This represents a decrease of 23.6% from the prior year.

Capital Expenditures
$28K
YoY+33.7%
5Y CAGR-29.3%

Geovax Labs Inc invested $28K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 33.7% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

GOVX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

GOVX quarterly income statement
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Revenue$0$0N/A$0-100.0%$852K-47.9%$1.6MN/A$2.8M
R&D Expenses$3.1M-20.3%$3.9MN/A$5.0M+6.7%$4.7M-11.7%$5.4MN/A$7.4M
SG&A Expenses$1.3M-2.8%$1.4MN/A$1.3M-13.8%$1.5M-8.6%$1.7MN/A$1.2M
Operating Income-$4.4M+15.8%-$5.3MN/A-$6.4M-17.6%-$5.4M-0.3%-$5.4MN/A-$5.9M
Interest ExpenseN/AN/AN/A$0$0N/AN/A$14K
Income Tax$0$0N/AN/A$0$0N/AN/A
Net Income-$4.4M+15.9%-$5.3MN/A-$6.3M-17.7%-$5.4M-0.2%-$5.4MN/A-$5.8M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Diluted).

GOVX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

GOVX quarterly balance sheet
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Total Assets$4.6M+55.7%$3.0M-53.0%$6.3M-5.8%$6.7M+25.8%$5.4M-50.6%$10.8M+32.8%$8.2M-26.6%$11.1M
Current Assets$4.2M+71.7%$2.4M-54.3%$5.3M-18.5%$6.5M+26.9%$5.1M-51.6%$10.6M+33.7%$7.9M-27.0%$10.9M
Cash & Equivalents$3.1M+147.2%$1.3M-58.8%$3.1M-38.4%$5.0M+61.9%$3.1M-58.4%$7.4M+35.1%$5.5M-35.9%$8.6M
Accounts ReceivableN/AN/A$0$0-100.0%$533K-64.4%$1.5M+127.1%$659K+20.4%$548K
Total Liabilities$2.9M+15.8%$2.5M-1.1%$2.5M+38.0%$1.8M-27.9%$2.5M-13.8%$2.9M-5.5%$3.1M+19.1%$2.6M
Current Liabilities$2.7M+18.4%$2.3M+18.3%$1.9M+6.2%$1.8M-27.9%$2.5M-13.8%$2.9M-5.5%$3.1M+19.1%$2.6M
Total Equity$1.8M+256.6%$494K-87.1%$3.8M-22.0%$4.9M+73.9%$2.8M-64.3%$7.9M+56.4%$5.0M-40.6%$8.5M
Retained Earnings-$160.5M-2.8%-$156.1M-3.5%-$150.8M-3.0%-$146.4M-4.5%-$140.1M-4.0%-$134.7M-4.1%-$129.4M-6.8%-$121.1M

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

GOVX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

GOVX quarterly cash flow statement
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Operating Cash Flow-$3.7M-3.4%-$3.5M+28.7%-$5.0M+20.1%-$6.2M-43.3%-$4.3M+27.3%-$6.0M+23.1%-$7.8M+16.6%-$9.3M
Capital Expenditures$0$0$0$0-100.0%$11K-36.6%$17K$0-100.0%$21K
Free Cash Flow-$3.7M-3.4%-$3.5M+28.7%-$5.0M+20.1%-$6.2M-43.0%-$4.3M+27.4%-$6.0M+22.8%-$7.8M+16.8%-$9.3M
Investing Cash Flow$0$0$0$0+100.0%-$11K+36.6%-$17K$0+100.0%-$21K
Financing Cash Flow$5.5M+220.8%$1.7M-43.3%$3.0M-62.6%$8.1M+3888536.4%$209-100.0%$7.9M+69.5%$4.7M-71.4%$16.3M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

GOVX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

GOVX quarterly financial ratios
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Operating MarginN/AN/AN/AN/A-635.8%-330.2%N/A-209.9%
Net MarginN/AN/AN/AN/A-630.1%-327.3%N/A-208.5%
Return on Equity-251.4%+814.2pp-1065.7%N/A-128.8%+61.6pp-190.3%-122.5pp-67.8%N/A-68.4%
Return on Assets-95.3%+81.1pp-176.4%N/A-93.9%+6.5pp-100.4%-50.9pp-49.5%N/A-52.3%
Current Ratio1.54+0.5x1.06-1.7x2.74-0.8x3.57+1.5x2.03-1.6x3.62+1.1x2.55-1.6x4.17
Debt-to-Equity1.64-3.4x5.04+4.4x0.66+0.3x0.37-0.5x0.90+0.5x0.37-0.2x0.62+0.3x0.31
FCF MarginN/AN/AN/AN/A-509.8%-365.5%N/A-334.0%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Frequently Asked Questions

What is Geovax Labs Inc's annual revenue?

Geovax Labs Inc (GOVX) reported $2.5M in total revenue for fiscal year 2025. This represents a -37.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Geovax Labs Inc's revenue growing?

Geovax Labs Inc (GOVX) revenue declined by 37.1% year-over-year, from $4.0M to $2.5M in fiscal year 2025.

Is Geovax Labs Inc profitable?

No, Geovax Labs Inc (GOVX) reported a net income of -$21.5M in fiscal year 2025.

Geovax Labs Inc (GOVX) had EBITDA of -$21.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Geovax Labs Inc (GOVX) has a return on equity of -561.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Geovax Labs Inc (GOVX) recorded an outflow of $21.5M in free cash flow during fiscal year 2025. This represents a 12.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Geovax Labs Inc (GOVX) recorded an outflow of $21.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Geovax Labs Inc (GOVX) had $6.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Geovax Labs Inc (GOVX) invested $28K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Geovax Labs Inc (GOVX) invested $18.1M in research and development during fiscal year 2025.

Geovax Labs Inc (GOVX) had 3M shares outstanding as of fiscal year 2025.

Geovax Labs Inc (GOVX) had a current ratio of 2.74 as of fiscal year 2025, which is generally considered healthy.

Geovax Labs Inc (GOVX) had a debt-to-equity ratio of 0.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Geovax Labs Inc (GOVX) had a return on assets of -338.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2025, Geovax Labs Inc (GOVX) held $3.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $21.5M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Geovax Labs Inc (GOVX) has an Altman Z-Score of -42.63, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Geovax Labs Inc (GOVX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Geovax Labs Inc (GOVX) reported a net loss of $21.5M while operations used $21.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Geovax Labs Inc (GOVX) scores 31 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top